Table 2.
Demographics and CSF MTBR-tau measures of participants in the pathologically confirmed primary tauopathy cohort
| Group | Normal controla | FTLD-TDPa | PiDa | AGDa | PSPa | CBDa | ADa | FTLD-MAPTa | Total |
|---|---|---|---|---|---|---|---|---|---|
| n | 29 | 21 | 5 | 2 | 22 | 18 | 10 | 5 | 112 |
| Autopsy-confirmed | 1 | 21 | 5 | 2 | 22 | 18 | 10 | 3 | 82 |
| Pure pathology | N/A | 14 | 5 | 1 | 14 | 13 | 10 | 1 | 58 |
| Copathology (n) | N/A | AD (1), AGD (1), HS + vascular (1), MND (4) | N/A | Vascular (1) | AD (5), LBD (2), vascular (1) | AD (3), PSP (1), LBD (1) | N/A | AD (1), HS (1) | 23 |
| Clinical syndromes | N/A | ALS + MCI (1), MCI (1), bvFTD (7), bvFTD + ALS (6), CBS (1), DLB (1), nfvPPA (1), nfvPPA + ALS (1), PPS (1), svPPA (1) | bvFTD (3), nfvPPA (2) | bvFTD (2) | CBS (5), nfvPPA (5), PAGF (1), PSP-RS (11) | bvFTD (4), CBS (9), nfvPPA (4), PSP-RS (1) | AD (1), AD + TES (1), EOAD (3), lvPPA (1), PCA (4) | Cognitively normal (2), bvFTD (2), nfvPPA (1) | 83 |
| Age at onset, SD | N/A | 60 ± 10 | 59 ± 4 | 53 ± 11 | 65 ± 7 | 60 ± 7 | 53 ± 4 | 49 ± 12 (3) | 60 ± 9 (81) |
| Age at CSF sampling, SD | 62 ± 13 | 64 ± 9 | 64 ± 9 | 68 ± 1 | 70 ± 7 | 64 ± 7 | 57 ± 5 | 50 ± 12 | 64 ± 10 |
| Interval between CSF collection and death, SD | 2 (1) | 2 ± 2 | 5 ± 2 | 0 ± 0 | 3 ± 2 | 3 ± 2 | 4 ± 1 | 2 ± 1 (3) | 3 ± 2 (82) |
| Duration, SD | N/A | 4 ± 4 | 6 ± 2 | 15 ± 11 | 5 ± 3 | 4 ± 1 | 5 ± 3 | 5 ± 5 (3) | 5 ± 4 (81) |
| Sex, M/F | 14/15 | 12/9 | 3/2 | 2/0 | 10/12 | 8/10 | 6/4 | 2/3 | 57/55 |
| CDR plus NACC FTLD SB score | 0.2 ± 0.5 (17) | 10.6 ± 5.1 (17) | 11.0 ± 2.1 (5) | 9.3 ± 3.2 (2) | 5.3 ± 3.1 (13) | 6.7 ± 3.7 (17) | 6.6 ± 2.2 (7) | 6.6 ± 6.3 (5) | 6.2 ± 5.0 (83) |
| CSF MTBR-tau275/t-tau, SD | 0.00657 ± 0.00078 | 0.00611 ± 0.00115 | 0.00676 ± 0.00138 | 0.00759 ± 0.00013 | 0.00669 ± 0.00091 | 0.00525 ± 0.00117 | 0.00472 ± 0.00085 | 0.00491 ± 0.00207 | 0.00608 ± 0.00126 |
| CSF MTBR-tau282/t-tau, SD | 0.01328 ± 0.00167 | 0.01203 ± 0.00193 | 0.01256 ± 0.00216 | 0.01526 ± 0.00054 | 0.01273 ± 0.00179 | 0.01007 ± 0.00191 | 0.00925 ± 0.00161 | 0.00963 ± 0.00457 | 0.01190 ± 0.00244 |
aNumbers in brackets indicate the number of available information within the group if limited. ALS, amyotrophic lateral sclerosis; DLB, dementia with Lewy bodies; EOAD, early-onset AD; lvPPA, logopenic variant of PPA; MCI: mild cognitive impairment; PAGF, pure akinesia with gait freezing; PCA, posterior cortical atrophy; PPS, pallidopyramidal syndrome; svPPA: semantic variant of PPA; TES, traumatic encephalopathy syndrome.